InsiderClue
Insiders · Profile

Allan Jonathan

GENERAL COUNSEL & CORP SEC at Stoke Therapeutics. Filing since 21 Jun 2023. CIK 0001966716

Company
Date
Role
Action
Shares
Amount
Of holding
STOK Stoke Therapeutics, Inc.
2 Oct 2026
GENERAL COUNSEL & CORP SEC
Sold on a plan
627
$16.51K
3.0%
STOK Stoke Therapeutics, Inc.
18 Aug 2026
GENERAL COUNSEL & CORP SEC
Sold at will
2,861
$91.64K
11.9%
STOK Stoke Therapeutics, Inc.
16 Jun 2026
GENERAL COUNSEL & CORP SEC
Sold on a plan
1,457
$43.64K
7.5%
STOK Stoke Therapeutics, Inc.
20 Mar 2026
GENERAL COUNSEL & CORP SEC
Sold on a plan
9,293
$313.04K
32.2%
STOK Stoke Therapeutics, Inc.
18 Mar 2026
GENERAL COUNSEL & CORP SEC
Sold at will
4,628
$145.06K
13.8%
STOK Stoke Therapeutics, Inc.
17 Mar 2026
GENERAL COUNSEL & CORP SEC
Sold at will
4,267
$140.84K
11.3%
STOK Stoke Therapeutics, Inc.
8 Dec 2025
GENERAL COUNSEL & CORP SEC
Sold on a plan
3,978
$128.41K
25.2%
STOK Stoke Therapeutics, Inc.
5 Dec 2025
GENERAL COUNSEL & CORP SEC
Sold on a plan
8,785
$274.90K
35.7%
STOK Stoke Therapeutics, Inc.
4 Dec 2025
GENERAL COUNSEL & CORP SEC
Sold on a plan
1,018
$31.42K
4.0%
STOK Stoke Therapeutics, Inc.
3 Dec 2025
GENERAL COUNSEL & CORP SEC
Sold at will
2,292
$70.25K
10.5%
STOK Stoke Therapeutics, Inc.
2 Dec 2025
GENERAL COUNSEL & CORP SEC
Sold at will
2,284
$68.02K
9.4%
STOK Stoke Therapeutics, Inc.
3 Oct 2025
GENERAL COUNSEL & CORP SEC
Sold on a plan
10,000
$250.65K
45.8%
STOK Stoke Therapeutics, Inc.
3 Sep 2025
GENERAL COUNSEL & CORP SEC
Sold on a plan
6,345
$127.32K
34.9%
STOK Stoke Therapeutics, Inc.
2 Sep 2025
GENERAL COUNSEL & CORP SEC
Sold on a plan
14,922
$300.49K
45.1%
STOK Stoke Therapeutics, Inc.
29 Aug 2025
GENERAL COUNSEL & CORP SEC
Sold on a plan
850
$17.00K
3.4%
STOK Stoke Therapeutics, Inc.
18 Aug 2025
GENERAL COUNSEL & CORP SEC
Sold at will
1,683
$30.69K
6.6%
STOK Stoke Therapeutics, Inc.
13 Aug 2025
GENERAL COUNSEL & CORP SEC
Sold on a plan
13,712
$205.68K
41.1%
STOK Stoke Therapeutics, Inc.
19 Mar 2025
GENERAL COUNSEL & CORP SEC
Sold at will
1,945
$16.09K
5.8%
STOK Stoke Therapeutics, Inc.
18 Mar 2025
GENERAL COUNSEL & CORP SEC
Sold at will
2,266
$19.65K
6.3%
STOK Stoke Therapeutics, Inc.
9 Dec 2024
GENERAL COUNSEL & CORP SEC
Sold on a plan
13,666
$185.98K
38.9%
STOK Stoke Therapeutics, Inc.
6 Dec 2024
GENERAL COUNSEL & CORP SEC
Sold at will
9,696
$123.89K
21.6%
STOK Stoke Therapeutics, Inc.
20 May 2024
GENERAL COUNSEL & CORP SEC
Sold on a plan
8,599
$129.33K
76.8%
STOK Stoke Therapeutics, Inc.
28 Mar 2024
GENERAL COUNSEL & CORP SEC
Sold on a plan
5,126
$67.67K
66.4%
STOK Stoke Therapeutics, Inc.
19 Mar 2024
GENERAL COUNSEL & CORP SEC
Sold at will
2,349
$14.33K
23.3%
STOK Stoke Therapeutics, Inc.
21 Jun 2023
General Counsel & Corp Sec
Sold on a plan
1,948
$26.25K
100%
25 decisions on file.